Management of Genital Melanoma
For genital melanoma, perform wide local excision with 1-2 cm margins (avoiding radical surgery when possible), assess lymph nodes via sentinel node biopsy if Breslow thickness ≥0.8mm, and strongly consider adjuvant immunotherapy (anti-PD-1 agents like nivolumab or pembrolizumab) for stage IIB or higher disease.
Key Diagnostic Considerations
Genital melanomas (vulvar, vaginal, cervical) represent a distinct subset of mucosal melanomas with unique characteristics 1:
- Mutation profile differs from cutaneous melanoma: Acral lentiginous and mucosal melanomas of the genital region have a higher probability of c-Kit mutations rather than BRAF mutations 1
- Mandatory mutation testing for BRAF, and consideration of NRAS and c-Kit testing in advanced disease (unresectable stage III or stage IV) 1, 2
- Histopathology must include Breslow thickness, mitotic rate, ulceration status, and margin clearance 2
Surgical Management
Primary Tumor Excision
The surgical approach for genital melanoma requires balancing oncologic adequacy with functional preservation 2, 1, 3:
Margin recommendations:
- In situ melanoma: 0.5 cm margins 2, 1
- Invasive melanoma ≤2 mm thickness: 1 cm margins 2, 1, 3
- Invasive melanoma >2 mm thickness: 2 cm margins 2, 1, 3
Critical caveat: Genital in situ melanoma has higher local recurrence rates than other anatomic sites 4. Despite these margin recommendations, achieving negative histologic margins is paramount—even if narrower functional margins are necessary to avoid pelvic exenteration 5, 6.
Lymph Node Assessment
Sentinel lymph node biopsy (SLNB) is recommended for 2, 3:
- Breslow thickness ≥0.8 mm with ulceration
- Breslow thickness 0.8-1.0 mm (with or without ulceration)
- All tumors >1 mm thickness
Complete lymph node dissection is NOT routinely recommended for sentinel node-positive patients based on recent evidence 2. However, for clinically detectable (macroscopic) lymph node metastases, complete lymph node dissection remains indicated 2.
Nodal status is the single most important independent prognostic factor for overall survival in both vulvar and vaginal melanoma 6, 7.
Staging Workup
Staging intensity depends on tumor thickness 1, 2, 3:
- Stage IA (pT1a): No imaging required
- Stage IB-IIIA (pT1b-pT3a): Ultrasound for locoregional lymph nodes
- Stage >IIIA (pT3a and higher): CT or PET scans before surgical treatment 1, 2
- Stage IIIB/IIIC: CT imaging prior to surgery with multidisciplinary review 4
Adjuvant Therapy
For resected stage IIB or higher disease, adjuvant immunotherapy is now standard of care 2, 8:
Preferred options (all Level I, Grade A evidence) 2:
- Nivolumab (anti-PD-1): 240 mg IV every 2 weeks or 480 mg every 4 weeks
- Pembrolizumab (anti-PD-1): 200 mg IV every 3 weeks (up to 2 years)
- Dabrafenib/trametinib (for BRAF-mutated disease): Combination targeted therapy
These recommendations are based on cutaneous melanoma trials, as genital melanomas lack dedicated prospective data 5, 9. However, the aggressive biology and poor prognosis of genital melanomas (median survival 22-30 months, 5-year survival 16-42% 10, 11, 7) strongly supports aggressive systemic therapy.
Management of Advanced/Metastatic Disease
For unresectable stage III or stage IV disease 2, 8:
First-line options:
- PD-1 blockade alone (nivolumab or pembrolizumab) for all patients regardless of BRAF status
- Ipilimumab plus nivolumab combination for higher response rates (particularly for brain metastases)
- BRAF/MEK inhibitor combinations (vemurafenib/cobimetinib, dabrafenib/trametinib) for BRAF-mutated disease
Important consideration: While c-Kit mutations occur in genital melanomas 1, 12, 1, c-Kit inhibitor data remains limited and should be considered only in clinical trials.
Follow-Up Strategy
Surveillance intensity correlates with stage 4, 3:
- Stage IA: 2-4 visits over 12 months, then discharge
- Stage IB-IIIA: Every 3 months for 3 years, then every 6 months to 5 years
- Stage IIIB/IIIC and resected stage IV: Every 3 months for 3 years, every 6 months to 5 years, then annually to 10 years 4
Imaging (CT chest/abdomen/pelvis) may be performed for stage IIB and higher for up to 3-5 years 3.
Critical Pitfalls to Avoid
Do not perform radical surgery (pelvic exenteration) as first-line treatment—wide local excision with negative margins provides equivalent survival with better quality of life 5, 6, 9
Do not skip mutation testing in advanced disease—c-Kit mutations are more common in genital melanomas than cutaneous melanomas 1
Do not withhold adjuvant immunotherapy based on mucosal location—while trial data is from cutaneous melanoma, the aggressive biology warrants treatment 5, 7, 13
Do not assume amelanotic lesions are benign—25% of genital melanomas present as amelanotic tumors 11
Breslow thickness and mitotic count remain the most important prognostic factors for disease-free survival 11, 6, 7